In Situ Modification of the Tumor Cell Surface with Immunomodulating Nanoparticles for Effective Suppression of Tumor Growth in Mice

Zheng, Chenguang; Wang, Qixue; Wang, Ying; Zhao, Xinzhi; Gao, Kaimin; Liu, Qi; Zhao, Yu; Zhang, Zhanzhan; Zheng, Yadan; Cao, Jingjing; Chen, Hongyun; Shi, Linqi; Kang, Chunsheng; Liu, Yang; Lu, Yunfeng

doi:10.1002/adma.201902542

Cited by 67 publications

(50 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two recent studies demonstrate that tumors can be coated with antibodies and antibody Fc fragments, exposing them to NK cell-mediated ADCC. These studies take advantage of specific biochemical characteristics of the TME, such as lower pH levels and high sialic acid expression, to directly coat tumors with antibody fragments (300,301). Subsequently, NK cells can recognize these Fc IgG fragments and become activated in-situ to promote tumor clearance in in-vivo models.…”

Section: Turning "Cold" Tumors "Hot" For Nk Cell Immune Surveillance mentioning

confidence: 99%

Unleashing Natural Killer Cells in the Tumor Microenvironment–The Next Generation of Immunotherapy?

2020

View full text Add to dashboard Cite

The emergence of immunotherapy for cancer treatment bears considerable clinical promise. Nevertheless, many patients remain unresponsive, acquire resistance, or suffer dose-limiting toxicities. Immune-editing of tumors assists their escape from the immune system, and the tumor microenvironment (TME) induces immune suppression through multiple mechanisms. Immunotherapy aims to bolster the activity of immune cells against cancer by targeting these suppressive immunomodulatory processes. Natural Killer (NK) cells are a heterogeneous subset of immune cells, which express a diverse array of activating and inhibitory germline-encoded receptors, and are thus capable of directly targeting and killing cancer cells without the need for MHC specificity. Furthermore, they play a critical role in triggering the adaptive immune response. Enhancing the function of NK cells in the context of cancer is therefore a promising avenue for immunotherapy. Different NK-based therapies have been evaluated in clinical trials, and some have demonstrated clinical benefits, especially in the context of hematological malignancies. Solid tumors remain much more difficult to treat, and the time point and means of intervention of current NK-based treatments still require optimization to achieve long term effects. Here, we review recently described mechanisms of cancer evasion from NK cell immune surveillance, and the therapeutic approaches that aim to potentiate NK function. Specific focus is placed on the use of specialized monoclonal antibodies against moieties on the cancer cell, or on both the tumor and the NK cell. In addition, we highlight newly identified mechanisms that inhibit NK cell activity in the TME, and describe how biochemical modifications of the TME can synergize with current treatments and increase susceptibility to NK cell activity.

show abstract

Section: Turning "Cold" Tumors "Hot" For Nk Cell Immune Surveillance mentioning

confidence: 99%

Unleashing Natural Killer Cells in the Tumor Microenvironment–The Next Generation of Immunotherapy?

2020

View full text Add to dashboard Cite

show abstract

“…Cellular backpacks using nanoparticles without being internalized also hold promise of targeted drug delivery and enhanced cancer immunotherapy, which integrates the respective merits of nanoparticles as drug depots and cells with natural directional migration potency as active carriage 143, 144. Huang et al reported nanoparticle-conjugated T cells for enhanced targeting of chemotherapeutics to disseminated tumor cells in lymph nodes 145.…”

Section: Engineering Cells Via Chemical Bioconjugationmentioning

confidence: 99%

Advances in Engineering Cells for Cancer Immunotherapy

Shen

et al. 2019

Theranostics

View full text Add to dashboard Cite

Cancer immunotherapy aims to utilize the host immune system to kill cancer cells. Recent representative immunotherapies include T-cell transfer therapies, such as chimeric antigen receptor T cell therapy, antibody-based immunomodulator therapies, such as immune checkpoint blockade therapy, and cytokine therapies. Recently developed therapies leveraging engineered cells for immunotherapy against cancers have been reported to enhance antitumor efficacy while reducing side effects. Such therapies range from biologically, chemically and physically -engineered cells to bioinspired and biomimetic nanomedicines. In this review, advances of engineering cells for cancer immunotherapy are summarized, and prospects of this field are discussed.

show abstract

“…In addition, a nondegradable CT‐CPNC was also designed to facilitate the recognition of tumor cells by natural killer (NK) cells to trigger antibody‐dependent cell‐mediated cytotoxicity for cancer immunotherapy. [ 55 ]…”

Section: Structures and Physicochemical Propertiesmentioning

confidence: 99%

Cargo‐Templated Crosslinked Polymer Nanocapsules and Their Biomedical Applications

Zhao

Chai

et al. 2021

Advanced NanoBiomed Research

Self Cite

View full text Add to dashboard Cite

Cargo‐templated crosslinked polymer nanocapsules (CT‐CPNCs) are mainly synthesized by in situ formation of crosslinked polymer shells on the surface of particulate cargoes, such as therapeutic proteins, siRNA/miRNA, liposomes, chitosans, metal‐organic frameworks (MOFs), and inorganic nanoparticles. CT‐CPNCs exhibit many advantages in biomedical applications, including 1) easy preparation and purification procedures, 2) high structural stability to inhibit undesired leakage of cargoes, and 3) high specific surface area for surface modification (e.g., loading of therapeutic agents and conjugation of targeting ligands). Importantly, CT‐CPNCs are designed with stimuli–responsive properties to release their cargoes in response to internal or external stimuli, including acidic pH values, redox potentials, enzymes (e.g., cathepsin B, hyaluronidase, and matrix metalloproteinases), light exposure, and heat. Herein, the design strategies and recent advances in CT‐CPNCs are focused upon and their potential applications are discussed. Furthermore, the advantages, limitations, future opportunities, and challenges of CT‐CPNCs are also discussed.

show abstract

In Situ Modification of the Tumor Cell Surface with Immunomodulating Nanoparticles for Effective Suppression of Tumor Growth in Mice

Cited by 67 publications

References 41 publications

Unleashing Natural Killer Cells in the Tumor Microenvironment–The Next Generation of Immunotherapy?

Unleashing Natural Killer Cells in the Tumor Microenvironment–The Next Generation of Immunotherapy?

Advances in Engineering Cells for Cancer Immunotherapy

Cargo‐Templated Crosslinked Polymer Nanocapsules and Their Biomedical Applications

Contact Info

Product

Resources

About